Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIFOUR study
2024-512052-38-00Phase 2Completed
- Sponsor
- Cantargia AB
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nadunolimab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Cantargia AB. Primary endpoints: Dose Limiting Toxicity (DLT) incidence in Phase 1b and Objective Response Rate (ORR) in Phase 2. Started Apr 2024; status: completed.
02
Drugs
nadunolimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512052-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512052-38-00.